GLOBALINK INVESTMENT INC.

Alps Group Inc operates in the biotechnology and healthcare services industries, focusing on the research and development of biologics and biopharmaceuticals, cellular therapy, medical testing laboratory and aesthetics beauty services, and the sale of medicine and healthcare products. The company's product pipeline remains in the preclinical stage, with none of its product candidates having obtained regulatory approval or commenced clinical trials. The industry is characterized by capital-intensive development, significant regulatory requirements, and competition based on brand recognition, product quality, price, and innovation.

The filing does not name specific primary competitors or provide market share data. The company's competitive positioning is implied through its focus on proprietary technology platforms including MyImmune, MyCelEst, and patient-derived organoid-based personalized cancer test development, as well as its intellectual property portfolio.

Alps Group generates revenue through four main streams: cellular therapy, medical testing laboratory and aesthetics beauty services, consultation fees, and the sale of medicine and healthcare products. Revenue is recognized at a point in time for goods or services transferred. The company operates through two reportable segments: Medical and Wellness, and Life Science, with an 'All Other' category for remaining activities.

The Medical and Wellness segment encompasses cellular therapy, medical testing laboratory and aesthetics beauty services, consultation fees, and the sale of medicine and healthcare products. For the fiscal year ended March 31, 2026, external sales from the Medical and Wellness segment were $23,486,000 ¹. The Life Science segment focuses on research and development of biologics and biopharmaceuticals, including the MyImmune and MyCelEst platforms, and patient-derived organoid-based personalized cancer test development. External sales from the Life Science segment were $0 ² for the same period. The 'All Other' segment reported external sales of $0 ³.

The company's product pipeline includes biologics and biopharmaceuticals, none of which have obtained regulatory approval, and none of its product candidates has commenced clinical trials. The company's technology platforms include MyImmune, MyCelEst, and patient-derived organoid-based personalized cancer test development. Alps holds intellectual property including trademarks, patents, and technical know-how of stem cells cultivation.

On October 28, 2025, Alps Group Inc completed a Business Combination with Globalink Investment Inc., whereby Globalink merged with and into the Company, and Merger Sub merged with and into Alps Holdco, resulting in Alps Holdco becoming a wholly-owned subsidiary of the Company. The Company's Ordinary Shares began trading on the Nasdaq Stock Market LLC under the symbol 'ALPS' on October 31, 2025. The Warrants are listed on the OTCID under the symbol 'ALPWF'. Simultaneously with the closing of the Business Combination, a PIPE Investment of $3,107,731 ⁴ for 310,788 ⁵ PubCo ordinary shares was consummated. The Merger Consideration Shares totaled 160,000,000 ⁶ PubCo ordinary shares, subject to the withholding of Escrow Shares. As of March 31, 2026, the issuer had 166,400,314 ⁷ Ordinary Shares, par value $0.0001 per share, issued and outstanding.

For the fiscal year ended March 31, 2026, total revenue was $23,486,000 ⁸, compared to $20,985,000 ⁹ in the prior fiscal year. Net income was $2,270,000 ¹⁰, compared to $1,985,000 ¹¹ in the prior year. The company's cash and bank balances as of March 31, 2026 were $3,107,731 ¹².

A primary growth vector is the advancement of the company's product pipeline, which includes biologics and biopharmaceuticals, none of which have obtained regulatory approval or commenced clinical trials. The company intends to use available resources to support the development of its product candidates and technology platforms, including MyImmune, MyCelEst, and patient-derived organoid-based personalized cancer test development. The filing does not provide a stated opportunity size or expected revenue contribution for these platforms.

Another growth vector is the expansion of the Medical and Wellness segment, which generated $23,486,000 ¹³ in external sales in fiscal 2026. The company's business model includes cellular therapy, medical testing laboratory and aesthetics beauty services, consultation fees, and the sale of medicine and healthcare products. The filing does not provide specific timelines or milestones for geographic expansion or new customer segments.

The filing does not provide specific margin trajectory, cost structure evolution, or efficiency targets with exact figures.

The filing does not provide specific supply chain posture, manufacturing capacity, technology infrastructure investments, or headcount strategy details.

The filing does not provide specific R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy with exact figures.

A key headwind is the capital-intensive nature of biotechnology product development, with significant uncertainties including costs associated with research and development activities, regulatory requirements, manufacturing capabilities, and potential commercialization efforts. The company expects to continue to incur significant expenses in connection with its ongoing activities, particularly as it advances the research and development of its product candidates and technology platforms.

A significant constraint is that the company's product pipeline remains in the preclinical stage, with none of its product candidates having obtained regulatory approval or commenced clinical trials. The company's ability to successfully undertake and complete pivotal clinical trials, secure regulatory approvals, scale up manufacturing, or engage in effective sales and marketing for product commercialization remains unproven.

Alps Group Inc is a recently formed public holding company with limited operating history, making it difficult to evaluate its business and prospects. The company's product pipeline remains in the preclinical stage, with none of its product candidates having obtained regulatory approval or commenced clinical trials, and its ability to successfully complete pivotal clinical trials, secure regulatory approvals, scale up manufacturing, or commercialize products is unproven. The company will need substantial additional funding to complete development of its product candidates, and obtaining financing may result in dilution to stockholders or impose burdensome debt covenants. As of March 31, 2026, cash and bank balances were $3,107,731 ¹⁴, which may be insufficient to fund the capital-intensive research and development activities required. The company faces risks related to the timing and progress of preclinical and clinical development, the number and scope of programs pursued, and the costs of maintaining intellectual property rights.

Management's message emphasizes the company's focus on advancing its research and development programs, including MyImmune, MyCelEst, and patient-derived organoid-based personalized cancer test development, following the successful completion of the Business Combination. The strategic priorities highlighted are the development of product candidates and technology platforms, securing additional financing to support ongoing activities, and managing the increased costs associated with being a newly listed public company, including legal, accounting, regulatory compliance, and corporate governance obligations.